AGENDA

1. Welcome and introduction

2. Apologies

3. Declarations of interest

4. Minutes of previous meeting

To protect commercial confidentiality the following appraisal will be held in private

5. Appraisal 1: Full Submission (WPAS)
Rolapitant (Varuby®) for the prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults.

6. The meeting will now open to the public

7. Chairman's report (verbal update)

8. AWMSG Five Year Strategy 2018-2023

9. National Prescribing Indicators 2017-2018 Data to September 2017

10. National Prescribing Indicators 2018-2019


12. Appraisal 2: Limited Submission
Lopinavir/ritonavir (Kaletra®) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus) infected children aged from 14 days to less than 2 years old

Appendices
13. **Appraisal 3: Limited Submission**  
   Lacosamide (Vimpat®) as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in children from 4 years of age to less than 15 years of age with epilepsy.

14. **Appraisal 4: Limited Submission**  
   Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza®) for the treatment of human immunodeficiency virus type 1 infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg).

15. **All Wales Guide: Pharmacotherapy for Smoking Cessation**

16. **Safe Use of Proton Pump Inhibitors**

17. **Common Ailments Service Formulary**

---

Date of next meeting – Wednesday, 14th March 2018 in Cardiff